When is growth factor (G‑CSF) support generally considered in pediatric chemotherapy?

• A. After regimens with high risk of febrile neutropenia or prolonged neutropenia, or after prior severe FN, following institutional guidelines.
• B. Only after any fever develops.
• C. Only after completing therapy.
• D. Never used in pediatrics.

Answer: (A)

G-CSF prophylaxis is used in pediatric chemotherapy to prevent neutropenia in situations where the chance of febrile neutropenia or prolonged neutropenia is high. In practice, this means giving growth factor support for regimens that carry a high FN risk or when a patient has had a prior severe febrile neutropenia. Clinicians follow institutional guidelines to balance benefits with cost and potential side effects, aiming to shorten neutropenia duration, reduce infection risk, and help maintain chemotherapy dose intensity. It is not given in response to fever after it develops, nor is it something reserved only after finishing therapy; and it is used in pediatrics when the risk assessment supports its use.